Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Abraxis BioScience LLC, part of Bristol Myers Squibb Co., is a company headquartered in Los Angeles, CA, involved in commercial physical and biological research.

Part of Beijing Wanger Biotechnology Co. Ltd., Beijing Kwinbon Biotechnology Co., Ltd. is a company headquartered in Changping District, China, that operates as testing laboratory specialized in research and development of rapid detection instrument and immunodiagnostic reagents for food safety.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Biological E. Ltd. is a way through which humanity expresses its fondness for life. At Biological E. Limited, we express this fondness through our continuous efforts to make disease prevention a distinct reality, with the recent genealogical innovations and mankind's ability to predict illness.

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women��s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer��s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

Serum Institute of India Pvt. Ltd. is the vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 140 countries across the globe in their national immunization programs, saving millions of lives throughout the world.

Beijing Weideweikang Biotechnology Co., Ltd., established on 2008-08-21, The business scope includes sales of biological detection reagents,medical instrumentsIkind,Class II;Equipment,electronic product,car,Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals);Technical Services,technology transfer;Agent import and export,Import and export,Technology Import and Export;Production of rapid test kits;Sales of veterinary diagnostic products of Beijing Mingrida Technology Development Co., Ltd.(For the name of the entrusted manufacturer and product category, see the valid entrustment or sales agreement,Does not contain mandatory immunization veterinary biological products)(Valid until2024year04moon28day);retail medicine;Sales of Class III Medical Devices.(Enterprises independently choose operating projects according to law,Carry out business activities;retail medicine,Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Merck Sharp & Dohme LLC, part of Merck & Co., Inc., is a company headquartered in Kenilworth, NJ, that operates as a pharmaceutical company.

SK bioscience Co., Ltd. engages in the development and distribution of bio and vaccine products. The company was founded on July 1, 2018 and is headquartered in Seongnam-si, South Korea.

AFFiRiS AG develops and produces vaccines for therapeutic treatment of chronic diseases. It provides research services and develops vaccines based on peptide antigens applied in the fields of biochemistry, molecular and cell biology, immunology and veterinary medicine. AFFiRiS was founded by Walter Schmidt and Frank Mattner in November 2003 and is headquartered in Vienna, Austria.

Nabi Biopharmacetuicals is a drug development company in Rockville, Maryland. Its principle product is NicVAX, a nicotine conjugate vaccine intended to reduce physical addiction to nicotine. The drug was developed with help from the U.S. National Institute of Drug Abuse, and showed promise in early studies, however, two successive phase III trials of the drug in 2009 and 2011 failed. On Thursday, November 8, 2012 the business combination of Nabi Biopharmaceuticals and Biota Holdings Limited became effective to create Biota Pharmaceuticals, Inc.